Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IMMX - ImmixBio surges on mice data for lead candidate in connective tissue cancer

IMMX - ImmixBio surges on mice data for lead candidate in connective tissue cancer

Immix Biopharma Inc.
Nano-cap biotech Immix Biopharma (NASDAQ:IMMX) climbed in the morning hours Friday on above average volume after announcing that its lead asset IMX-110 outperformed an FDA-approved cancer drug marketed by Johnson & Johnson (JNJ) in a mice study. The connective tissue cancer soft tissue sarcoma (STS) trial was designed to evaluate the clinical-stage candidate against approved treatments in mice. The data indicated that IMX-110 led to 75% survival compared to 0% survival for Trabectedin, which is marketed by the Janssen unit of Johnson & Johnson (JNJ) as Yondelis, the company said. IMX-110 is currently undergoing Phase 1b/2a clinical trials targeting soft tissue sarcoma and solid tumors. The $3 billion worth of STS market is expected to reach $6.5 billion by 2030.

For further details see:

ImmixBio surges on mice data for lead candidate in connective tissue cancer
Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...